Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α;
ERα) represent the single largest molecular subtype of breast cancer. More women …

Breast cancer is one of the most frequent malignancies among women worldwide. Based on
clinical and molecular features of breast tumors, patients are treated with chemotherapy …

PURPOSE To our knowledge, WSG-ADAPT-HR+/HER2–(ClinicalTrials. gov identifier:
NCT01779206; n= 5,625 registered) is the first trial combining the 21-gene expression …

Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with
oestrogen receptor positive (ER+) breast cancer (BC), but> 20% of patients will eventually …

Breast cancer is a heterogeneous disease comprising the estrogen receptor (ER)–positive
luminal subtype which is subdivided into luminal A and luminal B and ER-negative breast …

Background In biomedical research much effort is thought to be wasted. Recommendations
for improvement have largely focused on processes and procedures. Here, we additionally …

Neoadjuvant therapy, where patients receive systemic therapy before surgical removal of
the tumour, can downstage tumours allowing breast-conserving surgery, rather than …

Treatment for HR+/HER2+ patients has been debated, as some tumors within this luminal
HER2+ subtype behave like luminal A cancers, whereas others behave like non-luminal …

Approximately 70% of patients have breast cancers that are oestrogen receptor alpha
positive (ER+) and are therefore candidates for endocrine treatment. Many of these patients …

Importance In clinical practice, neoadjuvant endocrine therapy (NET) is rarely used despite
being an effective treatment modality able to downstage tumors and facilitate breast …